Why BGPT?
logo

Check Claims Before You Publish

See how your reported results read as versioned evidence records β€” linked to experiments and limitations.Know what the science actually supports before you trust the answer.

Press Enter ↡ to review claims



    Explore by Goal












     Quick Explanation


    What Jiahui Sun’s work looks like (based on the provided papers)
    • Computational, multi-cohort biomedical risk modeling (e.g., TP53-associated 7-gene signature + nomogram in pancreatic cancer) with reported cross-cohort AUCs and calibration.
    • Host–microbe proteomics / diagnostics using tongue-coating metaproteomics for gastric cancer screening, including time-series stability and multi-center validation of a microbial-protein classifier.
    • Mechanistic translational biology mixing in vitro and in vivo work (e.g., Cav-1–EGFR degradation axis in LUAD; HepG2 mechanistic metabolite signaling).



     Long Explanation


    Author Review (science strength): Jiahui Sun
    Scope note. The critique below is based only on the papers and extracted raw results you provided (multiple DOIs plus detailed per-study methodological/result fields). Where the provided data don’t include enough detail to verify a specific claim, I mark it as uncertain.
    1) Evidence-based strength signals (from your provided raw extracts)
    A. Multi-cohort prognostic modeling (PDAC / TP53-associated signature)
    • Uses three human cohorts (ICGC + two TCGA components) with a reported training/validation design and time-dependent ROC evaluation.
    • Reports a specific gene list + coefficients, enabling mechanistic follow-up and re-implementation checks.
    • Biology claims are computational (immune infiltration via deconvolution + pathway enrichment); causality is not established by the provided extract.
    B. Tongue-coating metaproteomics diagnostic classifier
    • Includes multi-center discovery + independent validation, and reports both host and microbial protein features.
    • Reports within-individual temporal stability in a small time-series cohort, supporting repeatability of at least some protein features.
    • Has meaningful but not definitive risk of diagnostic overfitting: a 50-feature ML classifier with strong performance in training and decreasing performance across validation cohorts. That decrease is expected, but the magnitude plus cohort-limited scope means generalization outside similar settings remains uncertain.
    C. Mechanistic translational studies (ADGV; CAV1–EGFR)
    • ADGV β†’ hypertriglyceridemia risk is supported by dual-cohort epidemiology (cross-sectional + prospective) plus a mechanistic HepG2 component.
    • CAV1 as tumor suppressor is supported by a pipeline that connects multi-dataset DEG/hub selection to wet-lab phenotypes (cell lines, tissue microarrays, xenografts).
    2) Key quantitative visuals (from provided raw extracts)
    2.1 PDAC TP53 signature discrimination (time-dependent AUCs)
    2.2 Tongue-coating metaproteomics classifier performance across splits
    2.3 Tick pathogen prevalence (Guangxi field survey)
    Citation for the pathogen rates: The extracted prevalence percentages are from the provided tick-population paper.
    3) Skeptical critique: what’s strong vs. what remains uncertain
    Strengths (supported by provided raw details)
    • Quantification and evaluation. Multiple studies report quantitative performance (AUCs, accuracy/sensitivity/specificity, hazard ratios/odds ratios, mechanistic molecular readouts) rather than only narrative claims.
    • Cross-cohort checks exist. At least in the computational and diagnostic examples, validation is not only a single holdout: multiple cohorts appear in the extracted design.
    • Mechanistic anchoring appears in wet-lab oriented papers. For ADGV and CAV1, the extracts include pathway-level molecular changes plus phenotype assays (cell viability/invasion/apoptosis; lipid gene expression/TG accumulation; xenograft growth).
    Major limitations / blind spots (what would most likely change conclusions)
    • Computational inference risks (confounding + deconvolution limits). In the PDAC signature, immune infiltration is inferred from bulk expression deconvolution, which can be sensitive to reference signatures, tumor purity, and technical batch effects; this is compatible with the extract being computational-only.
    • Cross-platform heterogeneity. The PDAC model explicitly combines mutation data and expression data from different platforms/cohorts (e.g., described microarray vs RNA-seq in the provided limitations), which can inflate or deflate performance if batch correction is imperfect.
    • ML diagnostic generalization remains uncertain. Tongue-coating metaproteomics pipelines are sensitive to sampling, storage, swab handling, and LC-MS/analysis differences; the extract notes cohort scope is Chinese and external validation in other populations is lacking.
    • Observational causality vs association. For ADGV, epidemiology can establish association but does not prove mechanism in humans; the mechanistic evidence is in HepG2 cells only.
    • Mechanistic completeness in CAV1–EGFR. The extract supports EGFR degradation involvement via degradation assay concept and signaling readouts, but the causal path is still dependent on endocytic/trafficking details not fully shown in the provided extract.
    What would most disprove the central claims?
    • PDAC: signature fails in truly independent external cohorts and/or no longer remains prognostic after stricter adjustment for clinical covariates and batch/platform differences.
    • Gastric cancer screening: the 50-protein classifier loses discrimination in non-Chinese populations and/or when sampling/processing is varied across labs.
    • ADGV: the ADGV association disappears after controlling for additional metabolic/inflammatory drivers and the hepatic effects fail to replicate in more physiologically relevant models.
    4) Overall scientific assessment (bounded by the provided data)
    Across the provided set, the author’s work shows both computational risk/diagnostic modeling and mechanistic experimentation in human-relevant systems (cells, tissues, sometimes xenografts), with quantitative reporting and some validation. However, several core conclusions remain conditional on limitations typical of multi-cohort bioinformatics (batch effects, deconvolution validity, cross-platform drift) and of biomarker diagnostics (sampling/LC-MS reproducibility and cross-population generalization).


    Feedback:    

    Updated: April 30, 2026

     BGPT Author Review


    Scientific Quality

    70%

    Based on the provided papers alone, the author demonstrates solid competence in quantitative biomedical analysis and at least some mechanistic experimental follow-through. Strengths include multi-cohort/validation designs and explicit reporting of model features/coefficients. Main scientific weaknesses (from the provided extracts) are typical: reliance on computational inference without experimental causality (especially immune-pathway deconvolution and ML biomarker claims), risk of batch/platform and sampling biases, limited generalization evidence for diagnostics, and incomplete mechanistic dissection in signaling/trafficking claims. Overall: good-to-strong execution, but not yet at the level where causal mechanisms are fully closed across independent settings.


    Communication Quality

    70%

    The provided extracts indicate clear methodological reporting (datasets, pipeline steps, key quantitative results) and practical outputs (AUCs, classifier metrics, gene lists). However, some mechanistic and falsification-critical details are not fully verifiable from the extract alone (e.g., how exactly degradation kinetics were established; how much the models address remaining confounding). Communication is likely adequate, but extract-level granularity limits certainty.


    Author Novelty

    60%

    The reviewed items include non-trivial combinations (e.g., TP53-associated multi-omics nomogram; tongue-coating metaproteomics diagnostic classifier; scaffold-driven metabolite association + HepG2 mechanism; CAV1–EGFR mechanistic framing). These are meaningful but not obviously paradigm-shifting; novelty seems incremental-to-moderate across established frameworks.


    Scientific Rigor

    70%

    Rigor is moderately strong: the extract shows validation attempts (external cohort(s)), explicit gene lists/coefficients, and multi-assay wet-lab logic in mechanistic papers. Rigor limitations are also visible: computational-only causality, platform heterogeneity concerns, potential overfitting/feature selection risk in ML diagnostics, and limited generalization beyond the studied cohorts/populations.

     Top Data Sources ExportMCP


     Analysis Wizard



    Generates Plotly charts comparing training vs external validation AUCs for the PDAC TP53 7-gene signature and visualizes metaproteomics classifier performance using the extracted accuracy/sensitivity/specificity/AUC metrics.



     Hypothesis Graveyard


    The biomarker signals in tongue-coating are purely random classifier artifacts with no biological link to mucosal defense or tumor microenvironment; this is less likely if temporal stability and consistent host keratin patterns remain reproducible across more independent cohorts.


    ADGV causes hypertriglyceridemia directly through ACC upregulation in the liver as a dominant mechanism; this is less likely if human replication shows ADGV association persists while HepG2-derived lipogenesis signatures fail in more physiologic hepatic models.

     Science Art


    Author Review: Jiahui Sun Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending